Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 6Lymphoid 6Plasma cell 5Tumor-Agnostic 2Thoracic 2Myeloid 2Gynecologic 2Genitourinary 2Breast 2Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Vomiting 1Postoperative Nausea and Vomiting 1Breast Carcinoma In Situ 1

Interventions

Paclitaxel 162Fulvestrant 157Trastuzumab 156pembrolizumab 146Letrozole 137Carboplatin 118pertuzumab 104Capecitabine 104Specimen Handling 102Cyclophosphamide 102Anastrozole 90palbociclib 86abemaciclib 82Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 74trastuzumab deruxtecan 68Radiotherapy 62Biopsy 59Surveys and Questionnaires 55Gemcitabine 53130-nm albumin-bound paclitaxel 53olaparib 52sacituzumab govitecan 51Blood Specimen Collection 51Standard of Care 49Taxes 48eribulin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Diphenhydramine × Breast × 1 year × Clear all
NCT02473042 2025-12-05

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

M.D. Anderson Cancer Center

Phase NA Completed
188 enrolled 11 charts
Breast

Breast Neoplasms, Vomiting, Postoperative Nausea and Vomiting

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡